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INTRODUCTION
In late 2019, the virus responsible for Covid-19 was 
identified and called SARS-CoV-2. In China, 5% of 
COVID-19 patients were admitted in ICU, 2,3% were 
ventilated and 1,4% died. In early 2020, COVID-19 
quickly spread in Europe and was responsible for high 
mortality. Since the start of the SARS-CoV-2 pandemic, 
the need for trials to assess the benefit of antiviral 
treatment, anti-cytokine drugs, convalescent plasma 
and hydroxychloroquine has been advocated by the 
world health organization. However, evidence of the 
efficacy of such strategies is still lacking.
OBJECTIVES
This observational multicentric study aimed to identify 
prognostic factors and therapies which could be 
valuable in mechanically ventilated COVID-19 patients 
for respiratory insufficiency.
METHODS
The method consisted in a multicentric retrospective 
analysis in all consecutive COVID-19 patients admitted 
to intensive care unit (ICU) and mechanically ventilated 
for more than 24 hours from March 1 to April 25, 2020, 
in 12 hospitals. The study protocol was approved by 
our Ethics Committee and, due to the retrospective 
nature of the data collected, no consent from the 
patient was required.
Admission date, age, sex, body mass index, underlying 
conditions, treatments, physiological values, use of 
vasopressors, renal replacement therapy (RRT) and 
extracorporeal membrane oxygenation (ECMO), 
duration of mechanical ventilation, length of ICU stay, 
ICU and ventilator-free days at day 42 were collected. 
The primary outcome was survival during the hospital 
stay. Secondary outcomes included use of 
vasopressors, RRT or ECMO, ICU and ventilator-free 
days at day 42, and evolution of the main physiological 
values between days 0 and 7. Simple and multiple time-
dependent Cox regression models were used to assess 
the effects of factors on survival.
RESULTS
Out of 2003 patients hospitalized for SARS-CoV-2, 361 were admitted to the participating ICUs, 
257 were ventilated for more than 24 hours and 247 were included in the study. The length of 
stay in ICU was 21 (12-32) days, the median survival time was 82 days, and the mortality rate 
was 45%. Corticosteroid therapy was started in 58 (23%) patients between days 0 and 7 of ICU 
admission and 225 (91%) received hydroxychloroquine alone or in combination with 
corticosteroid and/or azythromycin. Mortality of the patients who received corticosteroids was 
34% (20/58) while it was 48% (91/189) in patients who did not (p = 0,01) (Figure 1). Sixty-nine 
(28%) patients needed RRT and 215 patients (87%) were treated with norepinephrine during 
their ICU stay. Four patients (1,6%) were on ECMO. Using multiple regression, the predictors of 
mortality were age, creatinine value, mean arterial pressure lower than 70 mmHg, lymphocytes 
count on day 0 and absence of corticosteroid use (Table 1). Survival probability was significantly 
higher in patients who received corticosteroids (p = 0,01)(Figure 1). Survival probability was 75% 
at 23 days in patients who received corticosteroids versus at 10 days for those who did not.
Figure 1: Kaplan-Meier survival probability plot of COVID-19 patients treated with and without  
corticosteroids during their first week of mechanical ventilation  (adjusted p value = 0,01).
CONCLUSIONS
Retrospectively analyzing the data of a multicenter cohort, we observed that mortality of 
patients with SARS-CoV-2 pneumonia treated with mechanical ventilation was as high as 45% 
and median survival time was 82 days. In this series, the risk factors for mortality included age, 
renal and circulatory dysfunction, lymphopenia and the absence of corticosteroid use during 
the first week of mechanical ventilation. Corticosteroid therapy during the first week of 


















Male sex 172 (69.6) - 95 (69.9) 77 (69.4) 0.92 -
Age (years) 65 (57-72) - 63 (55-69) 69 (60-77) <0.0001 <0.0001
BMI (kg/m²) 29 (26-33) 14 29 (26-33) 30 (26-33) 0.88 -
Tobacco 21 (8.5) 1 8 (5.9) 13 (11.7) 0.05 0.07
Chronic kidney disease 26 (10.5) - 8 (5.9) 18 (16.2) 0.0007 0.71
Diabetes 88 (35.8) 1 48 (35.6) 40 (36.0) 0.98 -
Hypertension 141 (57.1) - 77 (56.6) 64 (57.7) 0.71 -
COPD 32 (13.0) - 13 (9.6) 19 (17.1) 0.09 0.63
Cancer 11 (6.1) 66 5 (5.3) 6 (7.0) 0.74 -
Immunodeficiency 16 (6.5) - 6 (4.4) 10 (9.0) 0.22 -
SOFA 6 (4-8) - 5 (3-7) 7 (5-9) <0.0001 0.27
PaO2 (mmHg) 74 (62-90) 25 72 (62-90) 75 (64-91) 0.95 -
FiO2 (%) 80 (60-90) 17 78 (60-90) 80 (65-100) 0.09 0.19
PaO2 / FiO2 103 (82-132) 25 108 (83-140) 96 (79-128) 0.83 -
Platelet count (10³/mm³) 207 (156-290) - 209 (160-285) 207 (155-293) 0.79 -
Bilirubin (mg/dl) 0.64 (0.49-0.94) 1 0.67 (0.50-0.97) 0.60 (0.42-0.93) 0.42 -
Glasgow coma scale = 15 185 (77.4) 8 109 (82.6) 76 (71.0) 0.05 0.49
Creatinin (mg/dl) 1.00 (0.78-1.37) 1 0.91 (0.71-1.21) 1.20 (0.88-1.73) <0.0001 <.0001
MAP < 70 mmHg 89 (36.0) - 37 (27.2) 52 (46.8) 0.0004 0.01
Norepinephrin use 128 (51.8) - 58 (42.6) 70 (63.1) 0.0021 0.41
Diuresis 1 <0.0001 0.25
≥ 500 ml/day 226 (91.9) 132 (97.1) 94 (85.5)
200-500 ml/day 11 (4.5) 4 (2.9) 7 (6.4)
≤ 200 ml/day 9 (3.7) 0 (0.0) 9 (8.2)
CRP (mg/l) 175 (108-258) - 172 (107-243) 179 (109-261) 0.33 -
D-dimer (ng/ml)* 1500 (868-3832) 84 1305 (843-3190) 1938 (990-4000) 0.13 -
Lymphocyte count (10³/mm³)* 0.80 (0.55-1.05) 2 0.84 (0.60-1.10) 0.75 (0.51-1.02) 0.06 0.02
Ferritin (mcg/l)* 1185 (582-3053) 163 1281 (578-2790) 1041 (587-3196) 0.43 -
Hydroxychloroquin use 225 (91.1) - 128 (94.1) 97 (87.4) 0.02 0.46
Azythromycin use 107 (43.3) - 59 (43.4) 48 (43.2) 0.82 -
Corticosteroids use 58 (23.5) - 38 (27.9) 20 (18.0) 0.05 0.01
Table 1: Baseline characteristics and treatment, and association with survival in mechanically ventilated COVID-19 patients
Abbreviations: BMI: body mass index; COPD: chronic obstructive pulmonary disease; SOFA: sequential organ failure 
assessment; MAP: mean arterial pressure; CRP: C- reactive protein. *Cox model on log-transformed values.
